When is less actually more with immunotherapy for metastatic colorectal cancer? Dr. Cathy Eng (@CathyEngMD) and Dr. Jun Gong (@jgong15) share how patient frailty, BRAF status, and the latest trial data shape their first-line decisions for MSI-high disease. Access the full episode in the BackTable app: backtable.com/shows/tumor-bo… This podcast is supported by Bristol Myers Squibb. #ONC75 #ColorectalCancer #Immunotherapy #mCRC #ClinicalTrial @Kate_Baker_MD @VUMCDiscoveries @CedarsSinai